Showing results (231-240 of 247) with videos related to

Sort By:
Pageof 25
Expert Review of Vaccines|September 1, 2022
Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and aboveZhuo-Pei Li, Yun-Feng Shi, Li-Hua Hou, et al.
The Lancet. Respiratory Medicine|May 23, 2022
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trialJing-Xin Li, Shi-Po Wu, Xi-Ling Guo, et al.
The American Journal of Pathology|January 22, 2018
Chd7 Is Critical for Early T-Cell Development and Thymus Organogenesis in ZebrafishZhi-Zhi Liu, Zi-Long Wang, Tae-Ik Choi, et al.
Signal Transduction and Targeted Therapy|July 16, 2021
Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trialsFan-Yue Meng, Fan Gao, Si-Yue Jia, et al.
The New England Journal of Medicine|October 23, 2009
A novel influenza A (H1N1) vaccine in various age groupsFeng-Cai Zhu, Hua Wang, Han-Hua Fang, et al.
Journal of Virology|August 2, 2013
Later passages of neural progenitor cells from neonatal brain are more permissive for human cytomegalovirus infectionXing Pan, Xiao-Jun Li, Xi-Juan Liu, et al.
The Lancet. Respiratory Medicine|March 10, 2023
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trialRong Tang, Hui Zheng, Bu-Sen Wang, et al.
The Lancet Regional Health. Western Pacific|June 7, 2023
Safety and immunogenicity of anKai Chu, Zhao-Feng Bi, Wei-Jin Huang, et al.
The Lancet Regional Health. Western Pacific|September 8, 2025
Immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil9 in Chinese women aged 18-26 years: three-year follow-up data from a randomised clinical trialGuo-Hua Zhong, Zhao-Feng Bi, Kai Chu, et al.
The Lancet Regional Health. Western Pacific|June 26, 2023
Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trialPeng-Fei Jin, Xi-Ling Guo, Jin-Bo Gou, et al.
Pageof 25